Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|June 5, 2025
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 studyAlice P Chen, Geraldine O'Sullivan Coyne, Pamela L Wolters, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Seminars in Oncology|September 25, 2016
The root causes of pharmacodynamic assay failureKatherine V Ferry-Galow, Hala R Makhlouf, Deborah F Wilsker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Cancer Chemotherapy and Pharmacology|September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignanciesLeonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2020
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 MutationEileen M O'Reilly, Jonathan W Lee, Mark Zalupski, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinomaMaeve A Lowery, David P Kelsen, Marinela Capanu, et al.
Pageof 11